Repligen Corp. (RGEN)
113.88
-3.73
(-3.17%)
USD |
NASDAQ |
Mar 20, 16:00
113.88
0.00 (0.00%)
After-Hours: 20:00
Repligen Research and Development Expense (Quarterly) : 12.18M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Masimo Corp. | 32.10M |
| Orthofix Medical, Inc. | 15.37M |
| InfuSystem Holdings, Inc. | -- |
| Tandem Diabetes Care, Inc. | 46.07M |
| Plus Therapeutics, Inc. | 2.941M |